Claims for Patent: 7,709,467
✉ Email this page to a colleague
Summary for Patent: 7,709,467
Title: | Apoptosis promoters |
Abstract: | Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed. |
Inventor(s): | Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Elmore; Steven W. (Northbrook, IL), Kunzer; Aaron R. (Schaumburg, IL), Lynch; Christopher L. (Trevor, WI), McClellan; William J. (Waukegan, IL), Park; Cheol Min (Gurnee, IL), Song; Xiahong (Grayslake, IL), Wang; Xilu (Grayslake, IL) |
Assignee: | Abbott Laboratories (Abbott Park, IL) |
Application Number: | 12/120,914 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,709,467 |
Patent Claims: | 1. A method of treating patient with a lymphoid malignancy of B-cell origin or a small cell lung cancer, the method comprising administering to said patient a
therapeutically effective amount of a compound having formula (II) ##STR00027## wherein X.sup.3 is Cl or F; X.sup.4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH.sub.3).sub.2, N(CH.sub.3)(CH(CH.sub.3).sub.2),
7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R.sup.0 is ##STR00028## wherein X.sup.5 is CH.sub.2, C(CH.sub.3).sub.2 or CH.sub.2CH.sub.2; X.sup.6 and X.sup.7 are both hydrogen or are both methyl; and X.sup.8 is F, Cl, Br or
I; or X.sup.4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH.sub.3)(CH(CH.sub.3).sub.2) or 7-azabicyclo[2.2.1]heptan-1-yl, and R.sup.0 is ##STR00029## X.sup.4 is N(CH.sub.3).sub.2 or morpholin-1-yl, and R.sup.0 is ##STR00030##
2. The method of claim 1, wherein the compound having formula (II) is N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)pip- erazine-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methy- l)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide. 3. The method of claim 1, wherein the compound is orally administered to the patient. 4. The method of claim 1, wherein the patient has a small cell lung cancer. 5. The method of claim 1, wherein the patient has a lymphoid malignancy of B-cell origin. 6. The method claim 5, wherein the lymphoid malignancy of B-cell origin is a non Hodgkin's lymphoma. 7. The method of claim 5, wherein the lymphoid malignancy of B-cell origin is a follicular lymphoma. 8. The method of claim 5 further comprising administering a therapeutically acceptable amount of etoposide to the patent. 9. The method of claim 5 further comprising administering a therapeutically acceptable amount of vincristine to the patent. 10. The method of claim 5 further comprising administering a therapeutically acceptable amount of rituximab to the patent. |
Details for Patent 7,709,467
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2025-05-12 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2025-05-12 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2025-05-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.